Studies of Platelet Activating Factor (PAF) Antagonists from Microbial Products. II. : Pharmacological Studies of FR-49175 in Animal Models

Abstract

Platelet activating factor (PAF) antagonistic action of FR-49175 was studied using in vivo models designated as PAF-induced bronchconstriction, hypotension and vascular permeability increase. This compound (0.1 mg/kg, i.v.) significantly inhibited PAF-induced bronchoconstriction in guinea-pigs. However, it did not prevent PAF-induced hypotension in rats or vascular permeability increase in mice. Furthermore, the effect of this compound against a systemic anaphylaxis model in guinea-pigs was examined, but it did not show any inhibition of antigen-induced mortality at the dose of 10 mg/kg, i.v.